Non-invasive PGT method shows diagnostic concordance with invasive biopsy in monogenic disease families

This methodological development study evaluated a new non-invasive preimplantation genetic testing (niPGT) methodology using cell-free DNA from spent embryo culture medium. The study analyzed 191 samples from 29 families affected by rare monogenic disorders, comparing results to invasive trophectoderm biopsy as a control. The method successfully amplified all 191 samples, enabled diagnosis of 220 out of 277 pathogenic alleles, and showed 100% concordance (220/220) with invasive biopsy diagnoses for those alleles. An exploratory polygenic risk assessment for Type II Diabetes was conducted for select embryos, though this was not the primary focus.

Safety and tolerability data were not reported in this methodological study. The authors note that trace DNA content, maternal cell contamination, and high allele drop-out rates are known barriers for niPGT in general, though these were not specifically assessed as limitations of this particular methodology.

The study represents a technological advance toward scalable niPGT that requires no modification to standard IVF workflows. However, this was a methodological development study rather than a clinical validation trial. The polygenic risk assessment component was exploratory and conducted only on select embryos. Broader clinical validation in diverse populations and conditions would be needed before clinical implementation.

Practice relevance is limited to demonstrating proof-of-concept for this specific methodology. The 100% concordance with invasive biopsy for diagnosed alleles is promising but requires confirmation in larger, prospective clinical studies. The exploratory nature of the polygenic risk assessment means those findings should be interpreted with particular caution.